Ann: Positive Preliminary Results from Adult Clinical Study-RAP.AX, page-172

All good if you just want some short term profit or to take advantage of the short term price fluctuations.

But addressing your long term holding statement, it's absolutely likely there will be revenue. The company has discussed many times the four potential revenue streams they can target http://www.resapphealth.com.au/solutions/ and are focused on the most appropriate stream currently being Telehealth (though are still working towards clinics and humanitarian organisations). Where they've stated that 30% of Telehealth consults are for respiratory diseases (see their last investor presentation) and there's no accurate remote diagnosis available (let alone one that can be directly integrated into the Telehealth platform). Telehealth is also a relatively new space, with huge projected growth in the years to come.

And given the high accuracy rating, where its higher than current methods as well as correctly diagnosing individuals that were initially missed by experienced clinicians using a stethoscope. As well as the cost and time of using the app vs the cost and time of current diagnosis tools (beyond a stethoscope; e.g. X-ray, CT, blood/sputum tests) are huge benefits for clinics too. So it's very likely with FDA approval, clinics will adopt this technology.

Then with regards to humanitarian efforts in developing countries. As there is currently no accurate/cheap/quick field testing device/instrument to use, where pneumonia alone is the leading cause of death for children there. It's almost guaranteed that ResApp will be utilised by humanitarian organisations there.

So that's already 3 revenue streams, all of which seem very likely to adopt this technology.

The fourth was of course direct to consumer. i.e. Getting the app from the App Store and then paying per use. I'm sure some will use it, but in my own valuation I'm assuming this will be the lowest contributor to revenue (though I could be wrong). So I don't put too much emphasis on this point. But there's no negative to going after this stream anyway, since operational costs are very low.

On the site they also mention they may share access to the data they gather to researchers. So this could potentially be a fifth revenue stream, though I haven't heard them discuss this much (maybe they have during one of the presentations?).

Now even disregarding all of that. Say the market potential of the product absolutely flops and they can't get any deals going. As long as they maintain these high levels of accuracy, the tech is still sound. In which case there's still the possibility of selling it to someone else. As many larger companies will jump at the chance of gaining exclusive rights to this tech. And for them a multi-billion dollar acquisition is nothing (companies have done that in the past not even with the mindset of acquiring the technology but rather to acquire the team behind it). And for those that aren't aware of the price range, it was originally at $1/share that they would consider, they then changed it to $2/share before they'd consider. The closer we get to FDA approval, I'm sure the more that value will change too.

So yeh if people want to trade the dips that is fine (there's plenty of money to be made here). But for those unsure of the long term potential here, you'd honestly be hard pressed to find other long term holds with as much potential as RAP has.